Benzinga · Aug 18, 2026
JP Morgan Maintains Overweight on Evolent Health, Raises Price Target to $6
JP Morgan analyst John Stansel maintains Evolent Health (NYSE:EVH) with a Overweight and raises the price target from $5 to $6.
EV
NYSE · EVH
Evolent Health, Inc.
Healthcare · Medical - Healthcare Information Services
$4.59
Up+$0.11 (+2.29%)
Updated Aug 28, 2026, 3:33 PM
SID Score
6.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 453.39M
- P/E ratio
- -3.35
- Dividend yield
- 0.00%
- 52-week range
- $2.10 – $6.26
- Volume
- 2.92M
- Avg. volume
- 3.7M
Price performance
EVH price history
1M range · 21 trading sessions · Daily adjusted prices
EVH closed at $4.59 after 21 trading sessions, up 44.34% for the selected period.
- Last close
- $4.59
- Period change
- +44.34%
- Period low
- $3.08
- Period high
- $4.92
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $4.93 | $4.93 | $4.56 | $4.59 | 2.92M |
| Aug 26, 2026 | $4.80 | $5.03 | $4.735 | $4.92 | 2.23M |
| Aug 25, 2026 | $4.72 | $4.955 | $4.595 | $4.89 | 2.87M |
| Aug 24, 2026 | $4.67 | $4.79 | $4.55 | $4.72 | 2.06M |
| Aug 21, 2026 | $4.65 | $4.745 | $4.555 | $4.74 | 1.94M |
| Aug 20, 2026 | $4.52 | $4.76 | $4.50 | $4.70 | 2.78M |
| Aug 19, 2026 | $4.63 | $4.645 | $4.47 | $4.58 | 2.56M |
| Aug 18, 2026 | $4.41 | $4.70 | $4.3424 | $4.58 | 3.48M |
| Aug 17, 2026 | $4.63 | $4.63 | $4.40 | $4.41 | 3.59M |
| Aug 14, 2026 | $4.67 | $4.74 | $4.515 | $4.68 | 2.3M |
| Aug 13, 2026 | $4.22 | $4.67 | $4.195 | $4.66 | 3.73M |
| Aug 12, 2026 | $4.10 | $4.40 | $4.02 | $4.17 | 3.66M |
| Aug 11, 2026 | $4.13 | $4.405 | $3.94 | $4.10 | 4.84M |
| Aug 10, 2026 | $3.89 | $4.205 | $3.86 | $3.93 | 3.69M |
| Aug 7, 2026 | $3.70 | $4.13 | $3.61 | $3.95 | 5.08M |
| Aug 6, 2026 | $4.08 | $4.15 | $3.535 | $3.59 | 7.28M |
| Aug 5, 2026 | $3.15 | $3.17 | $3.00 | $3.08 | 3.09M |
| Aug 4, 2026 | $3.14 | $3.18 | $3.01 | $3.11 | 2.86M |
| Aug 3, 2026 | $3.12 | $3.30 | $3.075 | $3.14 | 3.38M |
| Jul 31, 2026 | $3.15 | $3.25 | $2.95 | $3.09 | 4.52M |
| Jul 30, 2026 | $3.31 | $3.31 | $3.08 | $3.18 | 4.15M |
Latest EVH news
The latest Smart Investors Daily articles mentioning EVH.
Stock researchCompany · Overview
EVH research
Overview
Company profile and research snapshot.
Company profile
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $6.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 18, 2026 | JP Morgan | Overweight | — |
| Aug 17, 2026 | TD Cowen | Buy | — |
| Aug 12, 2026 | Truist Securities | Hold | — |
| Aug 11, 2026 | Citigroup | Buy | — |
| Aug 10, 2026 | Canaccord Genuity | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 17, 2026
TD Cowen Maintains Buy on Evolent Health, Raises Price Target to $6
TD Cowen analyst Charles Rhyee maintains Evolent Health (NYSE:EVH) with a Buy and raises the price target from $5 to $6.
Yahoo · Aug 16, 2026
1 Healthcare Stock Worth Your Attention and 2 We Brush Off
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 26.1% over the past six months, topping the S&P 500 by 13.1 percentage points.
Yahoo · Aug 15, 2026
5 Must-Read Analyst Questions From Evolent Health’s Q2 Earnings Call
Evolent Health’s second quarter results drew a significant positive market reaction, reflecting outperformance versus Wall Street’s expectations on both revenue and profitability. Management pointed to the successful launch of the Highmark contract and robust customer renewals as key drivers. CEO Seth Blackley specifically highlighted that clinical engagement metrics for new partnerships, such as Aetna and Highmark, were trending above target, signaling strong execution in the company’s core val
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
